α‐Galactosidase‐A Loaded‐Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration
暂无分享,去创建一个
J. Veciana | M. Garcia-Parajo | J. Corchero | S. Schwartz | A. Villaverde | F. Albericio | N. Ventosa | J. Faraudo | E. Elizondo | I. Abasolo | P. Gil | M. Royo | Marta Melgarejo | Daniel Pulido | S. Sala | Evelyn Moreno | E. González-Mira | Ingrid Cabrera | D. Bueno | Merche Rivas
[1] Yoram Tekoah,et al. Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease. , 2015, Molecular genetics and metabolism.
[2] Igor L. Medintz,et al. Understanding enzymatic acceleration at nanoparticle interfaces: Approaches and challenges , 2014 .
[3] Martin Lundqvist,et al. Nanoparticles: Tracking protein corona over time. , 2013, Nature nanotechnology.
[4] J. Veciana,et al. Multifunctional nanovesicle-bioactive conjugates prepared by a one-step scalable method using CO2-expanded solvents. , 2013, Nano letters.
[5] Luis M Liz-Marzán,et al. Physicochemical properties of protein-coated gold nanoparticles in biological fluids and cells before and after proteolytic digestion. , 2013, Angewandte Chemie.
[6] Kevin Braeckmans,et al. Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge. , 2013, ACS nano.
[7] M. Sabbatini,et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. , 2012, Molecular genetics and metabolism.
[8] N. Ferrer-Miralles,et al. Enzymatic characterization of highly stable human alpha-galactosidase A displayed on magnetic particles , 2012 .
[9] A. Bobkov,et al. Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide , 2011, Proceedings of the National Academy of Sciences.
[10] E. Vázquez,et al. Integrated approach to produce a recombinant, his‐tagged human α‐galactosidase a in mammalian cells , 2011, Biotechnology progress.
[11] M. Garcia-Parajo,et al. pH-responsive polysaccharide-based polyelectrolyte complexes as nanocarriers for lysosomal delivery of therapeutic proteins. , 2011, Biomacromolecules.
[12] Silvia Muro,et al. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[13] Vladimir P. Torchilin,et al. Liposomes as ‘smart’ pharmaceutical nanocarriers , 2010 .
[14] W. Sly,et al. New strategies for enzyme replacement therapy for lysosomal storage diseases. , 2010, Rejuvenation research.
[15] Erkki Ruoslahti,et al. Targeting of drugs and nanoparticles to tumors , 2010, The Journal of cell biology.
[16] A. Tylki-Szymańska,et al. Enzyme Replacement Therapy for Fabry Disease , 2009, Drugs.
[17] W. Parak,et al. Intracellular processing of proteins mediated by biodegradable polyelectrolyte capsules. , 2009, Nano letters.
[18] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[19] M. Barone,et al. The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[20] Brian J. Ell,et al. Syndecan-1 regulates αvβ3 and αvβ5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor , 2009, The Journal of experimental medicine.
[21] R. Schiffmann,et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. , 2008, Molecular genetics and metabolism.
[22] Kenneth A. Dawson,et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.
[23] J. Veciana,et al. Preparation of uniform rich cholesterol unilamellar nanovesicles using CO2-expanded solvents. , 2008, Langmuir : the ACS journal of surfaces and colloids.
[24] S. Ishii,et al. Active‐site‐specific chaperone therapy for Fabry disease , 2007, The FEBS journal.
[25] V. Torchilin. Targeted pharmaceutical nanocarriers for cancer therapy and imaging , 2007, The AAPS Journal.
[26] J. Shayman,et al. α-Galactosidase A in Vascular Disease , 2007 .
[27] Andrei L Lomize,et al. Positioning of proteins in membranes: A computational approach , 2006, Protein science : a publication of the Protein Society.
[28] J. Shayman,et al. An in vitro model of Fabry disease. , 2005, Journal of the American Society of Nephrology : JASN.
[29] D. Garboczi,et al. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. , 2004, Journal of molecular biology.
[30] Jean-Pierre Benoit,et al. Physico-chemical stability of colloidal lipid particles. , 2003, Biomaterials.
[31] S. Cheng,et al. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders , 2003, Gene Therapy.
[32] R. Hopkin,et al. Comparative evaluation of α-galactosidase A infusions for treatment of Fabry disease , 2003, Genetics in Medicine.
[33] S. Packman,et al. Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy , 2003, Annals of Internal Medicine.
[34] D. Curiel,et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. , 2002, Cancer research.
[35] J. Medin,et al. Gene therapy for Fabry disease , 2001, Journal of Inherited Metabolic Disease.
[36] C. Scriver. The Metabolic and Molecular Bases of Inherited Disease , 2001 .
[37] T. Murakami,et al. Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters. , 2000, International journal of oncology.
[38] B. Davidson,et al. Gene therapy for lysosomal storage diseases. , 1998, Molecular therapy : the journal of the American Society of Gene Therapy.
[39] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[40] J. Scheerer,et al. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. , 1981, Clinica chimica acta; international journal of clinical chemistry.
[41] R. Desnick,et al. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. , 1973, The Journal of laboratory and clinical medicine.
[42] Raymond A. Dwek,et al. Targeting glycosylation as a therapeutic approach , 2002, Nature Reviews Drug Discovery.
[43] R. Desnick,et al. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. , 2001, American journal of human genetics.
[44] Obert,et al. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry's disease , 2001 .
[45] H. Sakuraba,et al. Urinary excretion of the vitronectin receptor (integrin αVβ3) in patients with Fabry disease , 1999 .